Hanall Biopharma (009420) — Cash Flow Quality Index
Hanall Biopharma (009420) has a Cash Flow Quality Index of 24.56x as of September 2025. Operating cash flow of ₩7.34 Billion exceeds net income of ₩298.96 Million, indicating high earnings quality where cash backs reported profits. Explore 009420 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hanall Biopharma Cash Flow Quality Index (2016–2023)
Historical Cash Flow Quality Index for Hanall Biopharma across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 009420 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Hanall Biopharma (2016–2023)
Year-by-year earnings quality comparison for Hanall Biopharma. For live market cap and the full company financial profile, see 009420 market cap.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 8.45x | ₩29.64 Billion | ₩3.51 Billion | ▼ -33.3% |
| 2022 | 12.68x | ₩25.20 Billion | ₩1.99 Billion | ▲ +14992.1% |
| 2021 | 0.08x | ₩839.87 Million | ₩10.00 Billion | ▲ +97.7% |
| 2020 | 0.04x | ₩929.29 Million | ₩21.87 Billion | ▼ -96.0% |
| 2019 | 1.07x | ₩20.49 Billion | ₩19.17 Billion | ▲ +217.8% |
| 2018 | -0.91x | ₩-2.99 Billion | ₩3.30 Billion | ▼ -112.5% |
| 2017 | 7.25x | ₩42.14 Billion | ₩5.81 Billion | ▲ +271.8% |
| 2016 | 1.95x | ₩3.95 Billion | ₩2.03 Billion | — |